European Journal of Cancer
Volume 45, Issue 2 , Pages 248-260 , January 2009

Individual patient data analysis to assess modifications to the RECIST criteria

  • Jan Bogaerts

      Affiliations

    • European Organization for Research and Treatment of Cancer (EORTC) Headquarters, Avenue Mounierlaan, 83/11, Brussel 1200 Bruxelles, Belgium
    • Corresponding Author InformationCorresponding author: Tel.: +32 2 774 10 63; fax: +32 2 771 38 10.
    • ,
  • Robert Ford

      Affiliations

    • RadPharm, Princeton, USA
    • ,
  • Dan Sargent

      Affiliations

    • Mayo Clinic, Rochester, USA
    • ,
  • Lawrence H. Schwartz

      Affiliations

    • MSKCC, New York, USA
    • ,
  • Larry Rubinstein

      Affiliations

    • National Cancer Institute, Bethesda, USA
    • ,
  • Denis Lacombe

      Affiliations

    • European Organization for Research and Treatment of Cancer (EORTC) Headquarters, Avenue Mounierlaan, 83/11, Brussel 1200 Bruxelles, Belgium
    • ,
  • Elizabeth Eisenhauer

      Affiliations

    • National Cancer Institute of Canada – Clinical Trials Group, Kingston, ON, Canada
    • ,
  • Jaap Verweij

      Affiliations

    • Erasmus University Medical Center, Rotterdam, The Netherlands
    • ,
  • Patrick Therasse

      Affiliations

    • GlaxoSmithKline Biologicals, Rixensart, Belgium
    • ,
  • for the RECIST Working Party

Received 17 October 2008 ,Accepted 29 October 2008.

References 

  1. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92(3):
  2. Bontenbal M, Creemers G-J, Braun HJ, et al. Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre. JCO. 2005;23(28):7081–7088
  3. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 1. JCO. 2004;22(5):777–784
  4. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 2. JCO. 2004;22(5):785–794
  5. Jassem J, Pien´kowski T, Pluzanska A, et al. for the Central & Eastern Europe and Israel Paclitaxel Breast Cancer Study Group Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a Randomized Phase III Multicenter Trial. JCO. 2001;19(6):1707–1715
  6. Chan S, Friedrichs K, Noel D, et al. for the 303 Study Group Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. JCO. 1999;17(8):2341–2354
  7. Nabholtz JM, Falkson C, Campos D, et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a Randomized, Multicenter, Phase III Trial. JCO. 2003;21(6):968–975
  8. Mackey JR, Paterson A, Dirix L, et al. Final results of the phase III randomised trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) to FAC as first line chemotherapy (CT) for patients (pts) with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol. 2002;21:35a;[abstr 137]
  9. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. JCO. 2005;23(15):3502–3508
  10. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. JCO. 2005;23(25):5892–5899
  11. Paridaens R, Biganzoli L, Bruning P, et al. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over. J Clin Oncol. 2000;18(4):724–733
  12. Biganzoli L, Cufer T, Bruning P, et al. Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: the European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial. JCO. 2002;20(14):3114–3121
  13. Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase III Study of Erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial. JCO. 2007;25(12):1545–1552
  14. Köhne CH, van Cutsem E, Wils J, et al. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. JCO. 2005;23(22):4856–4865
  15. Casali PG, Garrett CR, Blackstein ME, et al. Updated results from a phase III trial of sunitinib in GIST patients (pts) for whom imatinib (IM) therapy has failed due to resistance or intolerance. 2006 ASCO Annual Meeting Proceedings Part I, JCO. 2006;24(18S (June 20 Suppl.)):9513
  16. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumors: Revised RECIST guideline (version 1.1). Eur J Cancer, 2009;45:228–47.
  17. Zacharia TT, Saini S, Halpern EF, Sumner JE. CT of colon cancer metastases to the liver using modified RECIST criteria: determining the ideal number of target lesions to measure AJR. 2006;186:
  18. Schwartz LH, Mazumdar M, Brown W, Smith A, Panicek DM. Variability in response assessment in solid tumors: effect of number of lesions chosen for measurement. Clin Cancer Res. 2003;9:4318–4323
  19. Hillman SL, An M-W, O’Connell MJ, et al. An evaluation of the optimal number of lesions needed for tumor evaluation using the RECIST criteria: A North Central Cancer Treatment Group (NCCTG) Investigation, submitted for publication.
  20. Ford R, Schwartz L, Dancey J, et al. Lessons learned from independent central review. Eur J Cancer. 2009;45:268–274
  21. Schwartz LH, Bogaerts J, Ford R, et al. Evaluation of lymph nodes with RECIST 1.1. Eur J Cancer. 2009;45:261–267
  22. Ratain MJ, Sargent DJ. Optimizing the design of phase II oncology trials: The importance of randomization. Eur J Cancer. 2009;45:275–280
  23. Dancey JE, Dodd LE, Ford R, et al. Recommendations for the assessment of progression in randomized cancer treatment trials. Eur J Cancer. 2009;45:281–289
  24. Hopper KD, Kasales CJ, Van Slyke MA. Analysis of interobserver and intraobserver variability in CT tumor measurements. AJR. 1996;167:851–854
  25. Preda L, Lovati E, Chiesa F, et al. Measurement by multidetector CT scan of the volume of hypopharyngeal and laryngeal tumours: accuracy and reproducibility. Eur Radiol. 2007;17:2096–2102
  26. Gietema HA, Schaefer-Prokop CM, Mali WPTM, et al. Pulmonary nodules: Interscan variability of semiautomated volume measurements with multisection CT – influence of inspiration level, nodule size and segmentation performance. Radiol. 2007;245:888–894
  27. Erasmus JJ, Gladish GW, Broemeling L, et al. Interobserver and Intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. JCO. 2003;21(13):2574–2582
  28. Punnen S, Haider MA, Lockwood G, Moulding F, O’Malley ME, Jewett MA. Variability in size measurement of renal masses smaller than 4 cm on computerized tomography. J Urol. 2006;176(6 Pt 1):2386–2390

PII: S0959-8049(08)00874-5

doi: 10.1016/j.ejca.2008.10.027

European Journal of Cancer
Volume 45, Issue 2 , Pages 248-260 , January 2009

Article Tools